Detailed disclosure is attached.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Gujarat Terce Laboratories shared its Q4 and FY26 results via investor presentation. Full-year revenue fell 5% to ₹4,747 lacs, but the company swung to a profit of ₹220 lacs versus a loss of ₹98 lacs in FY25, with PAT margin improving to 4.64% from -1.95%. Net worth strengthened by over 50% during the year. However, Q4 FY26 was weak on a sequential basis — revenue declined 8% to ₹1,140 lacs and EBITDA plunged 68% to ₹37 lacs, with margins compressing sharply to 3.24% from 9.25% a year ago. Despite the weak quarter, the company still posted a positive Q4 PAT of ₹10 lacs compared to a loss of ₹339 lacs in Q4 FY25. CEO Aalap Prajapati highlighted a focus on profitability, operational efficiency, brand equity, and financial discipline, calling FY26 a year of strengthening fundamentals. The company operates 8 leading brands across paediatrics, gynaecology, orthopaedics, and general medicine with 150 medical representatives covering 13 states.
Mixed picture for shareholders — the full-year turnaround to profit and 50%+ net worth growth is a positive structural story, but the steep Q4 revenue and EBITDA margin compression signals near-term pressure that may weigh on the stock in the short term.